

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: CGMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. 5189 **1703-011.US2** DANIEL E. AFAR 12/06/1999 09/455,486 01/29/2003 7590 22462 GATES & COOPER LLP **EXAMINER** HOWARD HUGHES CENTER NICKOL, GARY B 6701 CENTER DRIVE WEST, SUITE 1050 LOS ANGELES, CA 90045 PAPER NUMBER **ART UNIT** 1642 DATE MAILED: 01/29/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

-		Application No.	Applicant(s)	
Office Action Summary		09/455,486	AFAR ET AL.	
		Examiner	Art Unit	
		Gary B. Nickol Ph.D.	1642.	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
Status 1\⊠	Pasponsive to communication(s) filed on 08 C	October 2002		
1)⊠ 2a)⊠	Responsive to communication(s) filed on <u>08 October 2002</u> . This action is FINAL . 2b) ☐ This action is non-final.			
3)□	, —		prosecution as to the merits is	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims				
4)⊠ Claim(s) 1,4-18,20,21 and 24-48 is/are pending in the application.				
4a) Of the above claim(s) <u>4-18,20,21 and 24-43</u> is/are withdrawn from consideration.				
5)	5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>1 and 44-48</u> is/are rejected.				
7)	7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/or election requirement. Application Papers				
9)☐ The specification is objected to by the Examiner.				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a)				
1. Certified copies of the priority documents have been received.				
	2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).				
a) The translation of the foreign language provisional application has been received.				
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 26. 4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Informal Patent Application (PTO-152) 6) Other:				

Application/Control Number: 09/455,486

Art Unit: 1642

Request for Continued Examination

The request filed on 10-08-02 for a Continued Examination (RCE) under 37 CFR 1.114 based on parent Application No. 09/455486 is acceptable and a RCE has been established. An action on the RCE follows.

Claims 1, 4-18, 20-21, 24-48 are pending.

Claims 4-18, 20-21, 24-43 have been withdrawn from further consideration by the examiner under 37 CFR 1.142(b) as being drawn to non-elected inventions.

Claims 1, and 44-48 are currently under consideration.

Rejections Maintained:

Claims 1, and 44-48 remain rejected under 35 USC 112, 1st paragraph for the reasons of record (see Paper No. 23, Paper No. 16, pages 3-5, Paper No. 11, pages 6-11).

Applicants argue (Paper No. 25, page 4) that the positions taken by the Office do not take into account the usefulness of these antibodies in ascertaining whether or not a particular malignant tissue does or does not express STEAP-2 protein. Applicants submit that it is necessary to ascertain the presence of the target protein in order to determine whether treatment targeting this protein is useful. Applicants further argue that the presence of the STEAP-2 in normal prostate is not a barrier for such treatments since loss of the prostate is an acceptable outcome.

These arguments have been considered but are not found persuasive for reasons of record. Applicants have speculated on the alleged usefulness of the STEAP-2 protein only after

Application/Control Number: 09/455,486

Art Unit: 1642

its possible expression in malignant tissue. However, as set forth previously, the specification provides no exemplification of or guidance on how to use the protein in any predictable manner for immunotherapy of cancer. Thus, applicant's arguments have not been found persuasive and the rejection is maintained.

All other rejections and or objections are withdrawn in view of applicant's amendments and arguments there to.

Conclusion

This is a continuation of applicant's earlier Application No. 09/455486. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however,

Application/Control Number: 09/455,486 Page 4

Art Unit: 1642

event will the statutory period for reply expire later than SIX MONTHS from the mailing date of

this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 703-305-7143.

The examiner can normally be reached on M-F, 8:30-5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Gary B. Nickol, Ph.D. Examiner
Art Unit 1642

GBN January 21, 2003

ANTHONY C. CAPUTA
CUTETIVISORY PATENT EXAMINER
YECHNOLOGY CENTER 1600